Immunoconjugate Therapy of Hematologic Malignancies / Najlacnejšie knihy
Immunoconjugate Therapy of Hematologic Malignancies

Code: 01394048

Immunoconjugate Therapy of Hematologic Malignancies

by Steven T. Rosen, Timothy M. Kuzel

The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to hu ... more

241.93


Low in stock at our supplier
Shipping in 10 - 15 days

Potřebujete více kusů?Máte-li zájem o více kusů, prověřte, prosím, nejprve dostupnost titulu na naši zákaznické podpoře.


Add to wishlist

You might also like

Give this book as a present today
  1. Order book and choose Gift Order.
  2. We will send you book gift voucher at once. You can give it out to anyone.
  3. Book will be send to donee, nothing more to care about.

Book gift voucher sampleRead more

More about Immunoconjugate Therapy of Hematologic Malignancies

You get 603 loyalty points

Book synopsis

The hybridoma technique for producing monoclonal antibodies, developed by Drs. Kohler and Millstein in 1975, revolutionized the field of tumor immunology. It is now clear that there are antigens associated with or restricted to human neoplasms that have biologic significance. Monoclonal antibodies have already been demonstrated to have great immunodiagnostic value and it is anticipated that they will become a component of our therapeutic armamentarium. Most investigators in the field, however, feel that the true potential of monoclonal antibodies in cancer therapy remains to be determined. Clearly the most encouraging results have been witnessed in the treatment of hematologic malignancies. This volume of CANCER TREATMENT AND RESEARCH explores the current state of the art of immunoconjugate therapy of hematologic malignancies.§Immunoconjugate Therapy of Hematologic Malignancies provides an update of a rapidly advancing field. The preliminary experience of a number of investigators suggests a role for targeted therapy in the treatment of hematologic malignancies. At the present time, immunoconjugates have, in most instances, been reserved for patients with advanced refractory disease. However, it is anticipated in the future that these reagents will be utilized as a complement to traditional therapy or as post-remission consolidation in patients with minimal residual disease. The obstacles have been defined; solutions will require further research and creative imagination.

Book details

Book category Books in English Medicine Clinical & internal medicine Diseases & disorders

241.93

Trending among others



Collection points Bratislava a 2642 dalších

Copyright ©2008-24 najlacnejsie-knihy.sk All rights reservedPrivacyCookies


Account: Log in
Všetky knihy sveta na jednom mieste. Navyše za skvelé ceny.

Shopping cart ( Empty )

For free shipping
shop for 59,99 € and more

You are here: